Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer
View/ Open
Author
Speers, C.
Tsimelzon, A.
Sexton, K.
Herrick, A. M.
Gutierrez, C.
Hilsenbeck, S.
Chang, J.
Brown, P.
Published Version
https://doi.org/10.1158/1078-0432.CCR-09-1107Metadata
Show full item recordCitation
Speers, C., A. Tsimelzon, K. Sexton, A. M. Herrick, C. Gutierrez, A. Culhane, J. Quackenbush, S. Hilsenbeck, J. Chang, and P. Brown. 2009. “Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer.” Clinical Cancer Research 15 (20) (October 6): 6327–6340. doi:10.1158/1078-0432.ccr-09-1107.Abstract
Purpose—Previous gene expression profiling studies of breast cancer have focused on the entire genome to identify genes differentially expressed between estrogen receptor alpha (ER)-positive and ER-alpha-negative cancers.Experimental Design—Here we used gene expression microarray profiling to identify a distinct kinase gene expression profile that identifies ER-negative breast tumors and subsets ER-negative breast tumors into 4 distinct subtypes.
Results—Based upon the types of kinases expressed in these clusters, we identify a cell cycle regulatory subset, a S6 kinase pathway cluster, an immunomodulatory kinase expressing cluster, and a MAPK pathway cluster. Furthermore, we show that this specific kinase profile is validated using independent sets of human tumors, and is also seen in a panel of breast cancer cell lines. Kinase expression knockdown studies show that many of these kinases are essential for the growth of ERnegative, but not ER-positive, breast cancer cell lines. Finally, survival analysis of patients with breast cancer shows that the S6 kinase pathway signature subtype of ER-negative cancers confers an extremely poor prognosis, while patients whose tumors express high levels of immunomodulatory kinases have a significantly better prognosis.
Conclusions—This study identifies a list of kinases that are prognostic and may serve as druggable targets for the treatment of ER-negative breast cancer.
Other Sources
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763053/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29004172
Collections
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)